SCA
ALLO icon

Spearhead Capital Advisors’s Allogene Therapeutics ALLO Stock Holding History

Spearhead Capital Advisors’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-10,652
Closed -$274K – 178
2021
Q3 		$274K Sell
10,652
-425
-4% -$10.1K 0.04% 162
2021
Q2 		$289K Buy
+11,077
New +$316K 0.04% 179

Other funds holding ALLO

TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Spearhead Capital Advisors's ALLO Position: Q4 2021 in Review

Spearhead Capital Advisors sold out of Allogene Therapeutics (ALLO) in Q4 2021, closing a stake of 10,652 shares — an estimated $274K sold.

Spearhead Capital Advisors first reported a position in ALLO in Q2 2021 and held it in 2 quarters. The position peaked at $289K in Q2 2021. 177 funds tracked by Wall St. Rank hold ALLO as of Q4 2021.

  • Spearhead Capital Advisors reported no remaining Allogene Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Spearhead Capital Advisors sold 10,652 Allogene Therapeutics shares in Q4 2021, an estimated $274K.
  • Spearhead Capital Advisors first reported a position in Allogene Therapeutics in Q2 2021 and held it in 2 quarters.
  • Spearhead Capital Advisors's Allogene Therapeutics position peaked at $289K in Q2 2021.
  • 177 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q4 2021.

Based on Spearhead Capital Advisors's 13F filing for Q4 2021, filed 25 Jan 2022.